Abstract
Immune checkpoint blockade (ICB) induces peripheral CD8 T cell proliferation and facilitates mutation-derived neoantigen targets for CD8 T cell antitumor immunity but the kinetics of immune re-invigoration remain poorly understood. Adoptive Cell Therapy (ACT) by ex-vivo T cell expansion has proven effective in high-mutational cancers, yes approaches have largely been restricted to antigen-unspecific T cell expansion. Selective neoantigen-specific CD8 T cell (NART) expansion potentially warrants improved ACT prognosis.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
